Vyleesi and Gabapentin Interaction: Safety, Risks, and Clinical Guidance

Why This Interaction Matters

Bremelanotide (brand name Vyleesi) treats hypoactive sexual desire disorder (HSDD) in premenopausal women, while gabapentin is prescribed for epilepsy, neuropathic pain, and off-label conditions including restless legs syndrome and anxiety. The overlap in patient populations is significant. Women with chronic pain conditions frequently take gabapentin and may also carry an HSDD diagnosis, making co-prescription a realistic clinical scenario.

Neither drug is metabolized through cytochrome P450 enzymes, which eliminates the most common source of drug-drug interactions [1][2]. This absence of CYP-mediated conflict often leads clinicians to assume the combination is entirely benign. That assumption is incomplete. The real concerns are pharmacodynamic: both drugs produce central nervous system depression, both affect blood pressure regulation, and both depend on renal clearance for elimination. A 2019 pooled analysis of the RECONNECT trials (N=1,247) reported that 40% of bremelanotide-treated patients experienced nausea and 11% reported dizziness [3]. Gabapentin's prescribing information lists dizziness in 17-28% of patients depending on dose [2]. When these side-effect profiles stack, the clinical picture changes.

Pharmacokinetic Profile: No CYP Conflict, but Renal Overlap

The pharmacokinetic interaction risk between bremelanotide and gabapentin is minimal at the hepatic level but present at the renal level. Bremelanotide is a cyclic heptapeptide that undergoes hydrolysis rather than CYP-mediated oxidation. According to the FDA-approved label, bremelanotide "is not a substrate, inhibitor, or inducer of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4" [1]. Gabapentin similarly bypasses hepatic metabolism entirely, excreting unchanged in urine with a renal clearance of approximately 120-130 mL/min in healthy adults [2].

Where these two drugs converge is the kidney. Approximately 65% of a bremelanotide dose is eliminated renally [1]. Gabapentin is 100% dependent on renal excretion [2]. In patients with reduced glomerular filtration (eGFR <60 mL/min), both drugs accumulate. The FDA gabapentin label specifies dose reductions at every stage of renal impairment: 300 mg twice daily for eGFR 30-59 to 300 mg once daily for eGFR 15-29, and 300 mg every other day for eGFR <15 [2]. Bremelanotide's label does not mandate renal dose adjustment, but the clinical pharmacology section notes that AUC increased by 69% in subjects with severe renal impairment (eGFR <30 mL/min) compared to matched controls [1].

For any patient taking both drugs, a baseline metabolic panel with eGFR is a reasonable first step. Recheck renal function at least annually, or sooner if the patient reports new-onset nausea, prolonged dizziness, or facial flushing lasting beyond 4 hours after bremelanotide injection.

Pharmacodynamic Risks: Sedation, Blood Pressure, and Nausea

The pharmacodynamic interaction is where clinicians should focus attention. Three overlapping effect domains deserve individual consideration.

Central nervous system depression. Gabapentin binds the alpha-2-delta subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release [4]. This mechanism produces dose-dependent somnolence in 15-21% of patients in clinical trials [2]. Bremelanotide activates melanocortin-4 receptors (MC4R) in the CNS, and its label reports somnolence in a small percentage of users alongside the more common dizziness (11%) [1][3]. While neither drug is classified as a traditional CNS depressant, their combined sedative burden is additive. Patients should avoid driving or operating heavy machinery on the day they use both drugs concurrently.

Blood pressure modulation. Bremelanotide produces a transient, dose-dependent rise in systolic and diastolic blood pressure. In clinical trials, mean increases were 2.5 mmHg systolic and 1.9 mmHg diastolic, peaking approximately 2-4 hours post-injection [1][5]. These changes resolved within 12 hours in most subjects. Gabapentin, by contrast, can cause mild hypotension and peripheral edema [2]. The opposing directionality may seem to cancel out, but the sequence matters. A patient who takes gabapentin at bedtime and injects bremelanotide in the evening could experience a blood pressure spike followed by a relative drop as bremelanotide's effect wanes and gabapentin's mild hypotensive properties persist. Dr. Sheryl Kingsberg, lead investigator on the RECONNECT trials, noted that "the transient blood pressure effect of bremelanotide warrants monitoring in any patient with cardiovascular risk factors, particularly when combined with other vasoactive medications" [3].

Nausea. This is the most clinically relevant shared side effect. Bremelanotide causes nausea in 40.0% of treated patients versus 1.3% on placebo, making it the most common reason for discontinuation in the RECONNECT program [3]. Gabapentin-associated nausea occurs in approximately 5.7% of patients at standard doses [2]. When both drugs are active, nausea rates may compound. The practical mitigation is timing: injecting bremelanotide at least 1-2 hours after a gabapentin dose (rather than simultaneously) allows the gabapentin-related GI effects to stabilize before adding bremelanotide's MC4R-mediated nausea signal.

What DDI Databases Say About Severity

Major drug interaction databases classify the bremelanotide-gabapentin pair as low-to-moderate severity. The FDA label for bremelanotide specifically contrasts it with higher-risk combinations. The label carries a boxed warning only for the interaction with naltrexone, stating that bremelanotide "decreased the systemic exposure of naltrexone by approximately 45% when co-administered orally" [1]. No analogous warning exists for gabapentin.

Lexicomp and Micromedex do not list a direct monograph entry for this specific pair, which itself reflects the absence of a clinically significant pharmacokinetic interaction. The interaction risk is inferred from shared adverse-effect profiles rather than from altered drug levels. The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction does not address gabapentin co-administration specifically but recommends that prescribers "review all concomitant medications for additive CNS or cardiovascular effects before initiating bremelanotide" [6].

Monitoring Protocol for Co-Prescribed Patients

A structured monitoring approach reduces risk without requiring drug discontinuation.

Before first co-administration: Obtain baseline blood pressure (seated, 2 readings averaged), serum creatinine with calculated eGFR, and a side-effect history from both drugs used individually. If the patient reports significant nausea on bremelanotide alone, adding gabapentin's mild GI effects may push tolerability past a threshold. Consider an antiemetic pretreatment such as ondansetron 4 mg taken 30 minutes before bremelanotide injection.

First 30 days: Ask the patient to self-monitor blood pressure on days when both drugs are used. A home blood pressure reading exceeding 160/100 mmHg within 4 hours of bremelanotide injection warrants clinical reassessment. Track sedation severity on a simple 0-10 scale. Any score above 6 suggests the combined CNS load is excessive and gabapentin timing or dose should be adjusted.

Ongoing: Recheck renal function every 6-12 months. Both the American Academy of Family Physicians and the FDA recommend periodic renal monitoring for chronic gabapentin users [2][7]. If eGFR declines below 60 mL/min, reduce gabapentin per label guidance and consider extending the interval between bremelanotide doses to allow for slower renal clearance.

Dose-Adjustment Considerations

Bremelanotide's fixed-dose design (1.75 mg subcutaneous, PRN) limits titration options. The FDA label does not provide a lower dose recommendation for drug interactions [1]. Gabapentin, however, allows flexible dosing across a wide therapeutic range (300-3 to 600 mg/day for most indications) [2].

If additive side effects emerge, the most practical adjustment is reducing the gabapentin dose rather than altering bremelanotide. A patient on gabapentin 900 mg three times daily who reports severe dizziness on combination days might reduce to 600 mg on those specific days, maintaining the full dose on non-bremelanotide days. This approach preserves pain or seizure control while narrowing the pharmacodynamic overlap window.

Timing separation is equally effective. Gabapentin reaches peak plasma concentration in 2-3 hours, with effects sustained for 5-7 hours [2]. Bremelanotide peaks at approximately 1 hour post-injection [1]. Injecting bremelanotide at least 2 hours after the most recent gabapentin dose positions the peak plasma concentrations of the two drugs out of phase, reducing the maximum combined CNS burden.

Special Populations

Patients with renal impairment. As noted above, both drugs accumulate when kidney function declines. A patient with stage 3 chronic kidney disease (eGFR 30-59) on gabapentin 300 mg BID who adds bremelanotide may experience a disproportionate rise in bremelanotide exposure given the 69% AUC increase observed in severe impairment [1]. Conservative practice would limit bremelanotide to 4-6 doses per month rather than the maximum 8 in this population.

Older premenopausal women (ages 40-51). This group, while still premenopausal and eligible for bremelanotide, often has early declines in renal function not yet captured by standard creatinine-based eGFR equations. Cystatin C-based GFR estimation may provide a more accurate picture [8].

Patients on concomitant opioids. Gabapentin carries an FDA boxed warning regarding concomitant use with opioids due to respiratory depression risk [2]. Adding bremelanotide's mild CNS effects to a gabapentin-opioid regimen creates a three-drug sedative stack. The FDA's 2019 safety communication emphasized that "gabapentinoids combined with CNS depressants increase the risk of respiratory depression, even in patients without identified risk factors" [9]. Bremelanotide is not an opioid or traditional CNS depressant, but its additive dizziness and somnolence should factor into the overall risk assessment.

Patient Counseling Points

Patients prescribed both medications should receive clear guidance on five points. First, inject bremelanotide at least 1-2 hours after taking gabapentin. Second, do not drive or operate machinery on days when both drugs are used until you know how the combination affects you personally. Third, eat a light meal before the bremelanotide injection to reduce nausea. Fourth, check blood pressure at home within 2 hours of the injection if you have any history of hypertension. Fifth, report any new or worsening dizziness, prolonged facial flushing, or nausea lasting beyond 3 hours to your prescriber.

Patients should also understand that bremelanotide's maximum of 8 doses per month is a ceiling, not a target. Using fewer doses per month inherently reduces the number of days when the two drugs overlap, which lowers cumulative interaction exposure proportionally.